Our pipeline consists of highly differentiated molecules that were designed and optimized to effectively block key oncogenic pathways in hematological malignancies and solid tumors to address important unmet needs in patients with cancer.

We have developed a diverse pipeline consisting of four distinct programs that utilized three unique small molecule modalities, enzyme inhibition, disruption of protein-protein interactions, and targeted protein degradation. 

Our differentiation strategy is to design and optimize each of our small molecule therapeutics to possess specific properties that have the potential to benefit patients:

  • For PRT2527 (CDK9), we optimized for superior selectivity over previously developed CDK9i to improve tolerability
  • For PRT1419 (MCL-1), we optimized the PK profile that allows high target engagement for a short duration to avoid cardiotoxicity
  • For PRT3645 (CDK4/6), we focused on high selectivity and improved tissue penetration with low drug/drug interaction¬†
  • For PRT3789 (SMARCA2), we sought high selectivity over SMARCA4 to elicit synthetic lethality using a targeted protein degrader approach
ProgramCancer IndicationsDiscoveryPhase 1Phase 2/3Areas of Clinical Focus
PR-01
CDK9
PRT2527
Selected solid and hematologic malignancies
 
CLL, Lymphoma
MCL1
PRT1419
Selected hematologic malignancies and solid tumors
 
AML, CLL, Lymphoma
CDK4/6
PRT3645
Selected solid tumors
 
Breast Cancer, Gliomas, HNSCC, Lung Cancer, and Endometrial cancers
SMARCA2
PRT3789 (IV)
Multiple genomically-selected cancers
 
SMARCA4 mutated NSCLC and Other cancers
SMARCA2
(Oral)
Multiple genomically-selected cancers
 
SMARCA4 mutated NSCLC and Other cancers
New Programs
(Multiple Targets)
Selected solid and hematologic malignancies
 
Solid Tumors
Heme Malignancies
PR-01
CDK9
PRT2527
Selected solid and hematologic malignancies

Discovery

Phase 1

Phase 2

 
Areas of Focus: CLL, Lymphoma
MCL1
PRT1419
Selected hematologic malignancies and solid tumors

Discovery

Phase 1

Phase 2

 
Areas of Focus: AML, CLL, Lymphoma
CDK4/6
PRT3645
Selected solid tumors

Discovery

Phase 1

Phase 2

 
Areas of Focus: Breast Cancer, Gliomas, HNSCC, Lung Cancer, and Endometrial cancers
SMARCA2
PRT3789 (IV)
Multiple genomically-selected cancers

Discovery

Phase 1

Phase 2

 
Areas of Focus: SMARCA4 mutated NSCLC and Other cancers
SMARCA2
(Oral)
Multiple genomically-selected cancers

Discovery

Phase 1

Phase 2

 
Areas of Focus: SMARCA4 mutated NSCLC and Other cancers
New Programs
(Multiple Targets)
Selected solid and hematologic malignancies

Discovery

Phase 1

Phase 2

 
Areas of Focus: Solid Tumors
Heme Malignancies